🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Luckily, years of Deep Learning research have honed my ability to sit in front of a graph and refresh every few seconds.

Curious about COVID-19 vaccines? Tune in tomorrow to hear KizzyPhD's talk at 11:30am ET. Livestreaming details: bit.ly/700Covid

!

Sharing my simple talking points for people who are hesitant to get #CovidVaccine because they fear vaccine creation was rushed. 🧵

I will let the data speak for itself when it cleans itself

If you missed #WCM's COVID-19 vaccine ambassador training, the full session is now live on our YouTube channel! Help your loved ones make an informed decision about getting vaccinated. bit.ly/3ogRTOK

At #AACR23 the coming days with lots of folks from Niki Schultz's lab! Come say hi! Find us at the cBioPortal and OncoKB™ booths most days. Feel free to DM if u want to meet up

Thrilled to share our recent work in Cell ✨ We study the extent to which tumor suppressor genes in cancer adhere to Knudson's ‘two-hit’ hypothesis, and their clinical implications. 🧵👇 Also a detailed 🧵 by Ed Reznik below: MSK Department of Pathology & Laboratory Medicine Memorial Sloan Kettering Cancer Center

Increased KRAS mutant allele dosage is an important negative prognostic feature that will need to be integrated into clinical practice as we move into the era of 🎯 RAS-directed therapeutics for PDAC. 🔸️ Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS

🧬KRAS mutations in pancreatic cancer Nature Medicine 🚨95% of pancreatic cancers are KRAS mutant ❗️KRAS mut-allele dosage 🔺,OS🔻 ⁉️Targetting KRAS! 👉doi.org/10.1038/s41591… Eileen M O’Reilly Olca Basturk OncoAlert Dr Joseph McCollom DO Arndt Vogel #cancer #oncology #MedX

Excited to share our latest in Nature Medicine✨ We present a detailed clinico-genomic landscape of pancreatic adenocarcinomas With important implications for RAS 🎯 therapies Expertly co-led by Anna Varghese and Maria A Perry. w/Eileen M O’Reilly & colleagues Memorial Sloan Kettering Cancer Center

Paper: nature.com/articles/s4159… Data for 2,336 patients with PDAC on cBioPortal: cbioportal.org/study/summary?… MSK Department of Pathology & Laboratory Medicine MSKCC Center for Pancreatic Cancer Research MSK Department of Medicine

That KRAS Wild type #PancreaticCancer is a distinct entity from KRAS mutant disease was also recently reported by Eileen M O’Reilly & colleagues in their single institution study from Memorial Sloan Kettering Cancer Center in Nature Medicine nature.com/articles/s4159…

Featured today by MSK Library: Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer #BiallelicInactivation #TumorSuppressorGenes #LungCancer #CancerBiomarkers #KEAP1 #PrecisionOncology